JP2021532791A5 - - Google Patents

Info

Publication number
JP2021532791A5
JP2021532791A5 JP2021505666A JP2021505666A JP2021532791A5 JP 2021532791 A5 JP2021532791 A5 JP 2021532791A5 JP 2021505666 A JP2021505666 A JP 2021505666A JP 2021505666 A JP2021505666 A JP 2021505666A JP 2021532791 A5 JP2021532791 A5 JP 2021532791A5
Authority
JP
Japan
Prior art keywords
cancer antigen
sequence
cancer
chad
fragment
Prior art date
Application number
JP2021505666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532791A (ja
JPWO2020025642A5 (https=
Filing date
Publication date
Priority claimed from GBGB1812647.4A external-priority patent/GB201812647D0/en
Application filed filed Critical
Publication of JP2021532791A publication Critical patent/JP2021532791A/ja
Publication of JPWO2020025642A5 publication Critical patent/JPWO2020025642A5/ja
Publication of JP2021532791A5 publication Critical patent/JP2021532791A5/ja
Priority to JP2024103713A priority Critical patent/JP2024150469A/ja
Withdrawn legal-status Critical Current

Links

JP2021505666A 2018-08-03 2019-07-30 がんの予防または治療方法において使用するためのがん／精巣抗原をコードするウイルスベクター Withdrawn JP2021532791A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103713A JP2024150469A (ja) 2018-08-03 2024-06-27 がんの予防または治療方法において使用するためのがん／精巣抗原をコードするウイルスベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1812647.4 2018-08-03
GBGB1812647.4A GB201812647D0 (en) 2018-08-03 2018-08-03 Viral vectors and methods for the prevention or treatment of cancer
PCT/EP2019/070555 WO2020025642A1 (en) 2018-08-03 2019-07-30 Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103713A Division JP2024150469A (ja) 2018-08-03 2024-06-27 がんの予防または治療方法において使用するためのがん／精巣抗原をコードするウイルスベクター

Publications (3)

Publication Number Publication Date
JP2021532791A JP2021532791A (ja) 2021-12-02
JPWO2020025642A5 JPWO2020025642A5 (https=) 2022-08-08
JP2021532791A5 true JP2021532791A5 (https=) 2022-08-08

Family

ID=63518408

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021505666A Withdrawn JP2021532791A (ja) 2018-08-03 2019-07-30 がんの予防または治療方法において使用するためのがん／精巣抗原をコードするウイルスベクター
JP2024103713A Pending JP2024150469A (ja) 2018-08-03 2024-06-27 がんの予防または治療方法において使用するためのがん／精巣抗原をコードするウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103713A Pending JP2024150469A (ja) 2018-08-03 2024-06-27 がんの予防または治療方法において使用するためのがん／精巣抗原をコードするウイルスベクター

Country Status (10)

Country Link
US (1) US12180501B2 (https=)
EP (1) EP3829627A1 (https=)
JP (2) JP2021532791A (https=)
KR (1) KR20210041593A (https=)
CN (1) CN112789054A (https=)
AU (1) AU2019315700A1 (https=)
CA (1) CA3108350A1 (https=)
GB (1) GB201812647D0 (https=)
SG (1) SG11202101139XA (https=)
WO (1) WO2020025642A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022099543A1 (zh) * 2020-11-12 2022-05-19 深圳先进技术研究院 Ny-eso-1基因抑制剂作为抗肿瘤化疗药物增敏剂的应用
GB202400424D0 (en) * 2024-01-11 2024-02-28 Cancer Research Tech Ltd Treatment and prevention of lung cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140087A (en) 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
WO1998046769A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
ES2357960T3 (es) 1997-05-08 2011-05-04 Oncothyreon Inc. Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos.
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
JP2006149234A (ja) 2004-11-25 2006-06-15 Japan Science & Technology Agency プライム−ブーストワクチン接種法
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
EP2391638B1 (en) * 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
EP2601283B1 (en) 2010-08-06 2014-11-19 RE.LE.VI. S.p.a. A sanitary agent
EP2631290A4 (en) 2010-10-22 2015-06-10 Univ Hokkaido Nat Univ Corp VIRUS VECTOR FOR PRIME-BOOST VACCINES WITH VACCINIAVIRUS VECTORS AND SENDAIVIRUS VECTORS
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
GB201321384D0 (en) 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
WO2015092710A1 (en) * 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
WO2017120670A1 (en) 2016-01-11 2017-07-20 Brian Lichty Oncolytic virus and checkpoint inhibitor combination therapy
GB2549809C (en) * 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector

Similar Documents

Publication Publication Date Title
JP2021532791A5 (https=)
AU2023270200B2 (en) Chimeric poxvirus compositions and uses thereof
CN108430456B (zh) 癌症疫苗
JP2022003043A (ja) 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
ES2841075T3 (es) Enfoque de inmunoterapia de combinación para el tratamiento del cáncer
WO2018231759A1 (en) Pde5 compositions and methods for immunotherapy
EA018456B1 (ru) Новые иммуногенные эпитопы для иммунотерапии
JP2018519825A5 (https=)
Mirbahari et al. Recent progress in combination therapy of oncolytic vaccinia virus
EP4085137A1 (en) Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
US11629346B2 (en) Sting-dependent activators for treatment of disease
CN108085340A (zh) 一种同时表达靶向cd19和cd20的car与pd1-cd28嵌合受体的慢病毒载体
Bhagat et al. CEA vaccines
JP7643739B2 (ja) 遺伝子組換えワクシニアウイルス
Sultan et al. Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment
CN111225673A (zh) 亚德阿霉素组合治疗及方法
AU2020365525A1 (en) Vector for cancer treatment
US10584356B2 (en) Multigenome retroviral vector preparations and methods and systems for producing and using same
Aljabali et al. The dual promise of oncolytic viruses: selective targeting and therapeutic enhancement in cancer treatment
JPWO2020025642A5 (https=)
JP2022502066A (ja) 癌治療のための修飾ｂ５ｒ遺伝子を有する腫瘍溶解性ワクシニアウイルス
CA3133972A1 (en) Methods for inducing an immune response against neoantigens
JP2024534442A (ja) ネオ抗原アジュバント及び維持療法
WO2022150379A1 (en) Nk cell engager molecules and methods of use
US20240398865A1 (en) Tumor avatar vaccine compositions and uses thereof